ARTICLE | Company News
Harris FRC, Schwarz Pharma deal
January 4, 2000 8:00 AM UTC
Schwarz acquired from Harris worldwide rights, except Japan, to develop and commercialize Harkoseride (ADD 234037), a compound to treat central nervous system disorders that is in Phase II trials in epilepsy. ...